Navigation Links
AACR announces new journal, Cancer Discovery

PHILADELPHIA The American Association for Cancer Research announces the launch of its newest journal, Cancer Discovery, which will publish high-impact, peer-reviewed articles describing major advances in basic and clinical research. Its unique format will feature game-changing research, review articles, perspectives and commentaries, news, and "Research Watch" summaries of important journal articles. Cancer Discovery is a new addition to the AACR's robust publication program.

Cancer Discovery combines the expertise and experience of founding Editors-in-Chief Lewis C. Cantley, Ph.D., and Jos Baselga, M.D., Ph.D., along with full-time professional editors. Mark W. Landis, Ph.D., has been appointed executive editor.

"Cancer Discovery will make major contributions to the growing body of knowledge and be a touchstone for the diverse professional community in the cancer field," said Cantley.

Baselga added, "Topics will span the spectrum of cancer science and medicine; from the laboratory to the clinic to epidemiologic and prevention studies. This is a vital resource for everyone working on the problem of cancer."

"Facilitating communication and cross-disciplinary interactions in the field by publishing excellent journals is a core mission of the American Association for Cancer Research," said AACR Chief Executive Officer Margaret Foti, Ph.D., M.D. (h.c.). "We are thrilled that Cancer Discovery will provide a new publication outlet that captures the most significant work in the field and inspires thinking that will accelerate the pace of breakthroughs."

Cantley is director of the cancer center and chief of the division of signal transduction at Beth Israel Deaconess Medical Center. He is also professor of systems biology at Harvard Medical School. Cantley's laboratory discovered PI3 Kinase (PI3K) and revealed its role in a pathway that controls cell growth and cell transformation. PI3K is implicated in many cancers as well as in other diseases. As a result, pharmaceutical intervention in the PI3K pathway is being explored.

Baselga is chief of the division of hematology/oncology and associate director of the Massachusetts General Hospital Cancer Center. He is also professor of medicine at Harvard Medical School. Baselga's research focuses on the clinical development of novel, molecular-targeted agents for the therapy of cancer, particularly breast cancer. He conducted the initial clinical trials with the monoclonal antibodies cetuximab and trastuzumab and has been involved in the clinical development of several new agents including pertuzumab and PI3K inhibitors. His main focus in the laboratory and clinic is in the area of novel anti-HER2 agents, in the identification of mechanisms of resistance to anti-HER2 agents.

Landis was previously with Cell Press, most recently as senior editor for the journal Molecular Cell. Landis holds a doctorate in biological chemistry and molecular pharmacology from Harvard University, where his work focused on breast cancer. He has held research and teaching assistantships at Dartmouth College, the University of Massachusetts Medical School and Children's Hospital in Boston.


Contact: Michele Sharp
American Association for Cancer Research

Related biology news :

1. CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand
2. ClinOps Announces Appointment of New President and CEO
3. Aware, Inc. Announces Q310 Earnings Conference Call
4. NYSCF announces 2010 NYSCF Investigators
5. Onconova announces FDA agreement of a SPA for a pivotal phase 3 trial of Estybon in MDS
6. Penn Vet announces $100,000 winners of 2010 World Leadership Award and Student Inspiration Awards
7. TERMIS-North America announces speakers for annual event
8. American Society of Agronomy announces the class of 2010 Fellows
9. American Society of Agronomy announces award recipients
10. Biophysical Society announces 2011 society fellows
11. ActiveCare, Inc. Announces Capital Raise Commitment and Balance Sheet Restructuring
Post Your Comments:
(Date:11/17/2015)... , November 17, 2015 ... au 19 novembre  2015.  --> Paris ... --> DERMALOG, le leader de l,innovation biométrique, ... la fois passeports et empreintes sur la même surface ... les passeports et l,autre pour les empreintes digitales. Désormais, ...
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. ... human interface solutions, today announced expansion of its ... ™ touch controller and display driver integration ... of smartphones. These new TDDI products add to ... (HD resolution), TD4302 (WQHD resolution), and TD4322 (FHD ...
(Date:11/12/2015)... 2015   Growing need for low-cost, easy ... been paving the way for use of biochemical ... analytes in clinical, agricultural, environmental, food and defense ... in medical applications, however, their adoption is increasing ... continuous emphasis on improving product quality and growing ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is ... cancer biomarkers market with pharmaceutical companies and ... companion diagnostic tests. . ... Complete report on global cancer biomarkers ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015  Neurocrine ... Kevin Gorman , President and CEO of Neurocrine ... Jaffray Healthcare Conference in New York ... encouraged to visit the website approximately 5 minutes prior ... software.  A replay of the presentation will be available ...
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
Breaking Biology Technology: